{"id":9712,"date":"2026-03-25T16:21:55","date_gmt":"2026-03-25T08:21:55","guid":{"rendered":"https:\/\/regask.com\/?p=9712"},"modified":"2026-03-26T14:34:30","modified_gmt":"2026-03-26T06:34:30","slug":"fda-mhra-und-health-canada-kundigen-gemeinsames-symposium-zu-gcp-bioaquivalenz-und-pharmakovigilanz-an","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/","title":{"rendered":"FDA, MHRA und Health Canada k\u00fcndigen gemeinsames Symposium an\u2026"},"content":{"rendered":"<p>An <strong>10. M\u00e4rz 2026<\/strong>, Die <strong>US-amerikanische Food and Drug Administration (FDA)<\/strong>, in Zusammenarbeit mit der <strong>Arzneimittel- und Medizinproduktebeh\u00f6rde (MHRA)<\/strong> Und <strong>Gesundheit Kanada<\/strong>, gab eine Erinnerung f\u00fcr eine gemeinsame <strong>Hybridsymposium<\/strong> konzentriert auf <strong>Gute klinische Praxis (GCP)<\/strong>, <strong>Bio\u00e4quivalenz (BE)<\/strong>, Und <strong>Gute Pharmakovigilanzpraxis (GVP)<\/strong>. Geplant f\u00fcr <strong>2.\u20134. Juni 2026<\/strong>, Die Veranstaltung wird sich mit folgenden Themen befassen: <strong>sich wandelnde regulatorische Erwartungen<\/strong> und die Umsetzung von <strong>ICH E6(R3)<\/strong> in ganz Nordamerika und Gro\u00dfbritannien.<\/p>\n<div class=\"row\"  id=\"row-1551984919\">\n\n\t<div id=\"col-1105279480\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-175286549\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-175286549 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Details zum Update<\/h2>\n\t<div id=\"gap-1408746593\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1408746593 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Das Symposium wird Experten f\u00fcr Regulierungsfragen zusammenbringen, um zu diskutieren. <strong>aktuelle und zuk\u00fcnftige Anforderungen<\/strong> f\u00fcr <strong>klinische Studien<\/strong>, <strong>Bio\u00e4quivalenzstudien<\/strong>, Und <strong>Pharmakovigilanzpraktiken<\/strong>. Ein zentrales Thema wird die Umsetzung von <strong>ICH E6(R3)<\/strong>, die \u00fcberarbeitete Richtlinie, die einen Schwerpunkt legt <strong>qualit\u00e4tsorientierter und risikogerechter Ansatz<\/strong> zur Durchf\u00fchrung klinischer Studien.<\/p>\n<p>In den Sitzungen wird Folgendes untersucht <strong>Qualit\u00e4tsprinzipien<\/strong> in klinischen Forschungs- und Bio\u00e4quivalenzstudien, wobei hervorgehoben wird, wie diese Ans\u00e4tze in die Studienplanung und -durchf\u00fchrung integriert werden k\u00f6nnen. Dar\u00fcber hinaus werden Aktualisierungen zu folgenden Themen bereitgestellt: <strong>GVP-Anforderungen<\/strong> wird den f\u00fcr die <strong>\u00dcberwachung der Patientensicherheit<\/strong>.<\/p>\n<p>Die Regulierungsbeh\u00f6rden FDA, MHRA und Health Canada werden ebenfalls Einblicke geben zu <strong>Leitlinienentwicklung<\/strong>, <strong>Inspektionsbereitschaft<\/strong>, Und <strong>internationale Harmonisierungsbem\u00fchungen<\/strong>, und bietet damit eine regions\u00fcbergreifende Perspektive auf die Erwartungen an die Einhaltung der Vorschriften.<\/p>\n<p>Die Veranstaltung ist ab sofort buchbar und wird in folgender Form durchgef\u00fchrt: <strong>Hybridformat<\/strong>, Weitere Einzelheiten sind \u00fcber die FDA erh\u00e4ltlich. <strong>Unterst\u00fctzung f\u00fcr kleine Unternehmen und die Industrie<\/strong> Kan\u00e4le.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1105279480 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1354545714\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Veranstaltungsdatum<\/h2>\n\t<div id=\"gap-947420353\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-947420353 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Das Symposium findet statt vom <strong>2. Juni bis 4. Juni 2026<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1354545714 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1020336335\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Warum es wichtig ist<\/h2>\n\t<div id=\"gap-409725943\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-409725943 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Dieses Symposium bietet <strong>entscheidende regulatorische Klarheit<\/strong> bei der Annahme von <strong>ICH E6(R3)<\/strong> und seine Auswirkungen auf <strong>Qualit\u00e4ts-, Sicherheits\u00fcberwachungs- und Compliance-Rahmenbedingungen f\u00fcr klinische Studien<\/strong>. Es unterst\u00fctzt <strong>globale Ausrichtung<\/strong> \u00fcber Regulierungsbeh\u00f6rden hinweg und f\u00f6rdert <strong>effiziente, risikobasierte Ans\u00e4tze<\/strong> zur Arzneimittelentwicklung und zur Markt\u00fcberwachung.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1020336335 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2129733066\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Wen das betrifft<\/h2>\n\t<div id=\"gap-918763415\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-918763415 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Dieses Update ist relevant f\u00fcr <strong>Regulatorische Angelegenheiten<\/strong>, <strong>Qualit\u00e4tssicherung<\/strong>, <strong>Patientensicherheit<\/strong>, <strong>Recht\/Compliance<\/strong>, <strong>Forschung und Entwicklung<\/strong>, Und <strong>Vertriebsteams<\/strong> beteiligt an <strong>klinische Entwicklung, Bio\u00e4quivalenzstudien und Pharmakovigilanzaktivit\u00e4ten<\/strong> in pharmazeutischen Organisationen, die in Nordamerika und Gro\u00dfbritannien t\u00e4tig sind.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2129733066 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1042474557\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>N\u00e4chste Schritte<\/h2>\n\t<div id=\"gap-331563979\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-331563979 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Organisationen sollten <strong>Tagungsband des Monitor-Symposiums<\/strong> oder planen <strong>Nachbereitungsmaterialien pr\u00fcfen<\/strong> um zu beurteilen, wie <strong>ICH E6(R3)-Implementierung<\/strong> Aktualisierte regulatorische Anforderungen k\u00f6nnen sich auf laufende oder zuk\u00fcnftige klinische Programme auswirken. Teams sollten au\u00dferdem Folgendes ber\u00fccksichtigen: <strong>an der Veranstaltung teilnehmen<\/strong> um direkte Einblicke in die sich wandelnden Priorit\u00e4ten bei der Einhaltung von Vorschriften und der Inspektion zu gewinnen.<\/p>\n<p>Da sich die regulatorischen Anforderungen an die klinische Forschung und die Sicherheits\u00fcberwachung weltweit st\u00e4ndig weiterentwickeln, ist es unerl\u00e4sslich, \u00fcber harmonisierte Leitlinien informiert zu bleiben, um die Einhaltung der Vorschriften und die operative Einsatzbereitschaft aufrechtzuerhalten.<\/p>\n<p><a href=\"https:\/\/regask.com\/de\/\">RegASK<\/a> ist eine f\u00fchrende agentenbasierte KI-Plattform f\u00fcr regulatorische Analysen und Workflow-Orchestrierung, die globale Unternehmen in stark regulierten Branchen wie Konsumg\u00fcter und Life Sciences dabei unterst\u00fctzt, sich proaktiv in komplexen regulatorischen Umfeldern zu bewegen. Durch die Kombination von fortschrittlicher agentenbasierter KI mit Expertenwissen, <a href=\"https:\/\/regask.com\/de\/\">RegASK<\/a> liefert zeitnahe, vorausschauende und umsetzbare Erkenntnisse sowie eine durchg\u00e4ngige Automatisierung, optimiert Compliance-Prozesse, mindert Risiken und beschleunigt den Marktzugang in mehr als 160 L\u00e4ndern. <a href=\"https:\/\/regask.com\/de\/produkt\/\">Mehr erfahren<\/a> oder <a href=\"https:\/\/regask.com\/de\/demo-buchen\/\">Demo buchen<\/a> Jetzt.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1042474557 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1643840828\">\n\n\t<div id=\"col-78034409\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQs<\/h3>\n\t<div id=\"gap-1698497035\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1698497035 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>Welchen Zweck hat das Symposium von FDA, MHRA und Health Canada?<\/h4>\n\t<div id=\"gap-1725991061\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1725991061 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Das Symposium bietet aktuelle Informationen zu <strong>Regulatorische Erwartungen an GCP, Bio\u00e4quivalenz und Pharmakovigilanz<\/strong>, mit Schwerpunkt auf <strong>ICH E6(R3)-Implementierung<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-78034409 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-73953309\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Wann findet das Symposium statt?<\/h4>\n\t<div id=\"gap-126657476\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-126657476 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Es ist geplant f\u00fcr <strong>2.\u20134. Juni 2026<\/strong>, und wird in einem <strong>Hybridformat<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-73953309 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1213905407\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Welche Themen werden w\u00e4hrend der Veranstaltung behandelt?<\/h4>\n\t<div id=\"gap-1339103575\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1339103575 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Die Sitzungen werden folgende Themen behandeln <strong>Qualit\u00e4tssicherung durch Design in klinischen Studien<\/strong>, <strong>Bio\u00e4quivalenzstudien<\/strong>, <strong>GVP-Aktualisierungen<\/strong>, Und <strong>Internationale Bem\u00fchungen um eine Harmonisierung der Regulierungsbestimmungen<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1213905407 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-186062253\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Wie kann RegASK Teams unterst\u00fctzen, die sich auf ICH E6(R3) und die sich weiterentwickelnden GCP-Anforderungen vorbereiten?<\/h4>\n\t<div id=\"gap-2079771581\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2079771581 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"http:\/\/regask.com\/de\/\">RegASK <\/a>hilft Organisationen <strong>Regulatorische Aktualisierungen verfolgen<\/strong>, ausrichten <strong>Klinische und Sicherheitsprozesse mit globaler F\u00fchrung<\/strong>, und optimieren <strong>Compliance-Workflows<\/strong>, Unterst\u00fctzung der Bereitschaft f\u00fcr sich weiterentwickelnde GCP- und Pharmakovigilanzstandards.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-186062253 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On March 10, 2026, the U.S. Food and Drug Administration (FDA), in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada, issued a reminder for a joint hybrid symposium focused on Good Clinical Practice (GCP), bioequivalence (BE), and Good Pharmacovigilance Practice (GVP). Scheduled for June 2\u20134, 2026, the event will address&#8230;<\/p>","protected":false},"author":32,"featured_media":9713,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[530,33,35],"tags":[],"class_list":["post-9712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-north-america","category-news","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA MHRA and Health Canada Announce a Focus on GCP Practices<\/title>\n<meta name=\"description\" content=\"Learn about the upcoming symposium focused on GCP bioequivalence and pharmacovigilance hosted by the FDA, MHRA, and Health Canada.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/fda-mhra-und-health-canada-kundigen-gemeinsames-symposium-zu-gcp-bioaquivalenz-und-pharmakovigilanz-an\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA, MHRA, and Health Canada Announce Joint Symposium on GCP, Bioequivalence, and Pharmacovigilance\" \/>\n<meta property=\"og:description\" content=\"Learn about the upcoming symposium focused on GCP bioequivalence and pharmacovigilance hosted by the FDA, MHRA, and Health Canada.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/fda-mhra-und-health-canada-kundigen-gemeinsames-symposium-zu-gcp-bioaquivalenz-und-pharmakovigilanz-an\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T08:21:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-26T06:34:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hannah Nordin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hannah Nordin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/\"},\"author\":{\"name\":\"Hannah Nordin\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\"},\"headline\":\"FDA, MHRA, and Health Canada Announce Joint Symposium o&hellip;\",\"datePublished\":\"2026-03-25T08:21:55+00:00\",\"dateModified\":\"2026-03-26T06:34:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/\"},\"wordCount\":751,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png\",\"articleSection\":[\"North America\",\"Regulatory News\",\"Pharma and Biotech\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/\",\"name\":\"FDA MHRA and Health Canada Announce a Focus on GCP Practices\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png\",\"datePublished\":\"2026-03-25T08:21:55+00:00\",\"dateModified\":\"2026-03-26T06:34:30+00:00\",\"description\":\"Learn about the upcoming symposium focused on GCP bioequivalence and pharmacovigilance hosted by the FDA, MHRA, and Health Canada.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png\",\"width\":800,\"height\":600,\"caption\":\"Fda Launches Unified Adverse Event Monitoring System Aems Streamline Postmarket Safety Reporting\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\",\"name\":\"Hannah Nordin\",\"sameAs\":[\"https:\\\/\\\/regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA, MHRA und Health Canada k\u00fcndigen Schwerpunkt auf GCP-Praktiken an","description":"Informieren Sie sich \u00fcber das bevorstehende Symposium zum Thema GCP-Bio\u00e4quivalenz und Pharmakovigilanz, das von der FDA, der MHRA und Health Canada veranstaltet wird.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/fda-mhra-und-health-canada-kundigen-gemeinsames-symposium-zu-gcp-bioaquivalenz-und-pharmakovigilanz-an\/","og_locale":"de_DE","og_type":"article","og_title":"FDA, MHRA, and Health Canada Announce Joint Symposium on GCP, Bioequivalence, and Pharmacovigilance","og_description":"Learn about the upcoming symposium focused on GCP bioequivalence and pharmacovigilance hosted by the FDA, MHRA, and Health Canada.","og_url":"https:\/\/regask.com\/de\/fda-mhra-und-health-canada-kundigen-gemeinsames-symposium-zu-gcp-bioaquivalenz-und-pharmakovigilanz-an\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-25T08:21:55+00:00","article_modified_time":"2026-03-26T06:34:30+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png","type":"image\/png"}],"author":"Hannah Nordin","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Hannah Nordin","Est. reading time":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/#article","isPartOf":{"@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/"},"author":{"name":"Hannah Nordin","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65"},"headline":"FDA, MHRA, and Health Canada Announce Joint Symposium o&hellip;","datePublished":"2026-03-25T08:21:55+00:00","dateModified":"2026-03-26T06:34:30+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/"},"wordCount":751,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png","articleSection":["North America","Regulatory News","Pharma and Biotech"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/","url":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/","name":"FDA, MHRA und Health Canada k\u00fcndigen Schwerpunkt auf GCP-Praktiken an","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png","datePublished":"2026-03-25T08:21:55+00:00","dateModified":"2026-03-26T06:34:30+00:00","description":"Informieren Sie sich \u00fcber das bevorstehende Symposium zum Thema GCP-Bio\u00e4quivalenz und Pharmakovigilanz, das von der FDA, der MHRA und Health Canada veranstaltet wird.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/fda-mhra-and-health-canada-announce-joint-symposium-on-gcp-bioequivalence-and-pharmacovigilance\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting.png","width":800,"height":600,"caption":"Fda Launches Unified Adverse Event Monitoring System Aems Streamline Postmarket Safety Reporting"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Intelligentere Regulierungsentscheidungen erm\u00f6glichen","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65","name":"Hannah Nordin","sameAs":["https:\/\/regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/9712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=9712"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/9712\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/9713"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=9712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=9712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=9712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}